… The 5-year follow-up … of patients on the basis of tumor programmed cell death ligand-1
expression. In the future, the landmark analyses of progression-free survival or OS at 3 or 5 years …

… Encouraged by improved treatment outcomes with a biomarker-driven approach in advanced
NSCLC, and recognising the need to improve survival outcomes in early-stage NSCLC, …

… Here, we report the results of the planned secondary end point of 3-year overall survival …
tumor DNA (ctDNA) and compare its capacity to predict long-term survival with classical survival …

… percutaneous ablation for patients with stage 1 non-small cell lung cancer (NSCLC); however,
the … review and meta-analysis aims to compare surgery with ablation for stage 1 NSCLC. …

… The actual 5-year survival rate for stage I lung cancer can range from 56% to 92% in the
United States. It has been proposed that the reasons for this variability in cancer survival may …

… Immunotherapy has led to great breakthroughs in cancer treatment. Nivolumab, an anti-…
patients with non-small cell lung cancer (NSCLC) as a second or later line treatment. Two …

… treatment for patients with early-stage resectable non-small-cell lung cancer (NSCLC) is
surgery… has been associated with 5-year survival rates ranging from 41% in those with stage IIIA …

… (EGFR) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC).
5-year survival rate of N1N2 were 38%-50% in IASLC staging system. Here, we present the …

… subjects diagnosed with advanced lung cancer (20–30%) and their prognosis, estimated in
… dismal, with better survival outcomes for patients candidate to carboplatin doublets [5]. The …

… 48,296 non-small cell lung cancer (NSCLC) patients analyzed … % of all patients with lung
cancer are still alive 5 years after … , AC patients have a significantly better 5-year overall survival …